Literature DB >> 25794126

Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014).

Damiano Stefanello1, Paolo Buracco, Silvia Sabattini, Riccardo Finotello, Chiara Giudice, Valeria Grieco, Selina Iussich, Massimiliano Tursi, Timothy Scase, Stefano Di Palma, Giuliano Bettini, Roberta Ferrari, Marina Martano, Francesca Gattino, Mary Marrington, Monica Mazzola, Maria Elisabetta Vasconi, Maurizio Annoni, Laura Marconato.   

Abstract

OBJECTIVE: To compare the Kiupel (2 categories) and Patnaik (3 categories) histologic grading systems for predicting the presence of metastasis at the time of initial examination in dogs with cutaneous mast cell tumors (MCTs).
DESIGN: Retrospective case series. ANIMALS: 386 client-owned dogs with cutaneous MCTs. PROCEDURES: Medical records of dogs with newly diagnosed, histologically confirmed cutaneous MCTs that had undergone complete clinical staging were reviewed for clinical and histopathologic data.
RESULTS: All Patnaik grade 1 MCTs (n = 52) were classified as Kiupel low-grade MCTs, and all Patnaik grade 3 MCTs (43) were classified as Kiupel high-grade MCTs. Of the 291 Patnaik grade 2 MCTs, 243 (83.5%) were classified as Kiupel low-grade tumors, and 48 (16.5%) were classified as Kiupel high-grade MCTs. Dogs with Patnaik grade 3 MCTs were significantly more likely to have metastases at the time of initial examination than were dogs with grade 1 or 2 MCTs (OR, 5.46), and dogs with Kiupel high-grade MCTs were significantly more likely to have metastases than were dogs with Kiupel low-grade MCTs (OR, 2.54). However, 3 of 52 (5.8%) dogs with Patnaik grade 1 tumors, 48 of 291 (16.5%) dogs with Patnaik grade 2 tumors, and 44 of 295 (14.9%) dogs with Kiupel low-grade tumors had metastatic disease. CONCLUSIONS AND CLINICAL RELEVANCE: Findings indicated that in dogs with cutaneous MCTs, prognostication should not rely on histologic grade alone, regardless of grading system used, but should take into account results of clinical staging.

Entities:  

Mesh:

Year:  2015        PMID: 25794126     DOI: 10.2460/javma.246.7.765

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  17 in total

1.  Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.

Authors:  Hiroyuki Mochizuki; Rachael Thomas; Scott Moroff; Matthew Breen
Journal:  Chromosome Res       Date:  2017-01-05       Impact factor: 5.239

2.  Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.

Authors:  Johanna E Todd; Sandra M Nguyen; Joanna White; Veronika Langova; Penelope M Thomas; Sophia Tzannes
Journal:  Can Vet J       Date:  2021-12       Impact factor: 1.008

3.  Τhe Effect of Opioid Administration on Cytologic and Histopathologic Diagnosis of Canine Cutaneous Mast Cell Tumors Treated by Surgical Excision.

Authors:  Christina Marouda; Tilemahos Anagnostou; Ioannis Savvas; Lysimachos G Papazoglou; Dimitra Psalla
Journal:  Vet Sci       Date:  2022-04-22

4.  Canine mast cell tumours part I: Clinical and survival outcomes.

Authors:  Vanessa S Tamlin; Cynthia D K Bottema; Lucy Woolford; Elizabeth C Dobson; Allan E Kessell; Anne E Peaston
Journal:  Vet Med Sci       Date:  2022-05-03

5.  Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors.

Authors:  Jennifer K Hay; Victoria S Larson
Journal:  Can Vet J       Date:  2019-12       Impact factor: 1.008

6.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

7.  Epidemiology of Breed-Related Mast Cell Tumour Occurrence and Prognostic Significance of Clinical Features in a Defined Population of Dogs in West-Central Italy.

Authors:  Alessio Pierini; George Lubas; Eleonora Gori; Diana Binanti; Francesca Millanta; Veronica Marchetti
Journal:  Vet Sci       Date:  2019-06-06

Review 8.  Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.

Authors:  Michael Willmann; Emir Hadzijusufovic; Olivier Hermine; Mauro Dacasto; Laura Marconato; Karin Bauer; Barbara Peter; Susanne Gamperl; Gregor Eisenwort; Erika Jensen-Jarolim; Mathias Müller; Michel Arock; David M Vail; Peter Valent
Journal:  Vet Comp Oncol       Date:  2018-09-24       Impact factor: 2.613

9.  Identification of molecular genetic contributants to canine cutaneous mast cell tumour metastasis by global gene expression analysis.

Authors:  Kelly Bowlt Blacklock; Zeynep Birand; Deborah Biasoli; Elena Fineberg; Sue Murphy; Debs Flack; Joyce Bass; Stefano Di Palma; Laura Blackwood; Jenny McKay; Trevor Whitbread; Richard Fox; Tom Eve; Stuart Beaver; Mike Starkey
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

10.  The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

Authors:  Fabio Gentilini; Maria Elena Turba; Claire Dally; Masamine Takanosu; Sena Kurita; Makoto Bonkobara
Journal:  BMC Vet Res       Date:  2020-02-19       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.